Cart summary

You have no items in your shopping cart.

Denifanstat

SKU: orb1308311

Description

Denifanstat (FASN-IN-2, TVB-2640) is a selective, orally active fatty acid synthase (FASN) inhibitor with reported IC50 and EC50 values of 0.052 µM and 0.072 µM, respectively. By inhibiting FASN, denifanstat reduces de novo lipogenesis, a key pathway involved in fatty acid production and metabolic regulation.

Research Area

Metabolism Research

Images & Validation

−

Key Properties

−

CAS Number	1399177-37-7
MW	439.55
Purity	99.44% (May vary between batches)
Formula	C₂₇H₂₉N₅O
SMILES	Cc1n[nH]c(n1)-c1cc(C(=O)N2CCC(CC2)c2ccc(cc2)C#N)c(C)cc1C1CCC1
Target	Fatty Acid Synthase
Solubility	DMSO: 262.5 mg/mL (597.2 mM), sonication is recommended.

Customer Validated Data

−

The data below is submitted by researchers worldwide. We provide this transparency to help you decide if this product works for your specific application or species, even if we haven't tested it ourselves.

Success by Application

Reactivity Distribution

Latest Experiments

5 Results

Dilution

Sample

Summary

In vitro

Human

1 μM

HCT116 cells and 786-O cells

Denifanstat was used as a FASN...

In vitro

Human

1 μM

HeLa/DDP cells

Denifanstat was used as a FASN...

In vivo

Mouse

12 mg/kg

Xenograft tumors in mice

Denifanstat was used as a FASN...

In vitro

Human

5 mM

PC-3M cells and C4-2B cells

Denifanstat was used as a FASN...

In vivo

Mouse

100 mg/kg

Xenograft tumors in mice

Denifanstat was used as a FASN...

Bioactivity

−

Target IC50	FASN:0.072 μM (EC50)\|FASN:0.052 μM
In Vivo	METHODS: To assay antitumor activity in vivo, Denifanstat (100 mg/kg, 30% PEG400) was administered by gavage to SCID mice bearing PC-3M/HOXB13KD xenografts once daily for six weeks. RESULTS: Five weeks after inoculation, HOXB13-KD mice showed significant metastasis in IVIS, which was completely alleviated by Denifanstat treatment.Denifanstat treatment significantly prolonged metastasis-free survival in both control and HOXB13-KD mice.
In Vitro	METHODS: MDA-MD-231 and MDA-MB-231-BR cells were treated with Denifanstat (1-10.3 µM) for 6-30 h. Cell migration was detected by wound healing assay. RESULTS: Cell migration was inhibited in MDA-MB-231-BR cells but not in parental MDA-MD-231 cells in a dose-dependent manner.

Storage & Handling

−

Storage	-20°C
Expiration Date	12 months from date of receipt.
Disclaimer	For research use only

Alternative Names

−

ASC40, ASC-40, ASC 40, COVID-19, Denifanstat, Inhibitor, FASN-IN-2, FASN, Fatty Acid Synthase (FASN), Fatty Acid Synthase, FattyAcidSynthase, inhibit, SARS-CoV2, spike, protein, TVB 2640, TVB2640, TVB-2640

Quality Guarantee

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at [email protected].

Compound Identifiers

PubChem CID

Key Properties

−

No computed properties available.

Protocol Information

Find More Protocols

Email

[email protected]

UK Office

+44 (0)1223 859353

US Office

+1 (415) 906-5211

CN Office

+86 (27)-87663101

Distributors

biorbyt.com/distributor